Search

Displaying results 2581 - 2590 of 2865 in total
  1. Drug

    GDC-0623

    go.drugbank.com/drugs/DB11982
    Investigational

    GDC-0623 has been used in trials studying the treatment of Solid Cancers.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates
  2. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    Diacerein

    go.drugbank.com/drugs/DB11994
    ApprovedInvestigationalWithdrawn

    Diacerein is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including severe diarrhea . Diacerein is und...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  4. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    Avatrombopag (Doptelet), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation, thereby decreasing the need for blood transfusions. Patient...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  5. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various bio...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates
  7. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Naftopidil

    go.drugbank.com/drugs/DB12092
    Investigational

    Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Vinpocetine

    go.drugbank.com/drugs/DB12131
    Investigational

    Vinpocetine has been investigated for the treatment of Epilepsy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    BMS-275183

    go.drugbank.com/drugs/DB12144
    Investigational

    BMS-275183 has been used in trials studying the treatment of Tumors and Non-small Cell Lung Cancer.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates